Bristol Myers Squibb and Nvidia said they will expand AI infrastructure to build what BMS calls the “most powerful” AI factory in life sciences. The company plans to deploy Nvidia DGX SuperPOD systems with AIDGX Vera Rubin NVL72 capabilities, adding energy-efficient computational capacity for research and operational workflows. The expansion deepens a relationship that began three years ago when BMS deployed DGX SuperPOD infrastructure for R&D activities. BMS said the new setup will be a single-owned Nvidia infrastructure, aiming to increase scientific productivity by reducing manual work for researchers and improving program-selection probability. BMS also pointed to other AI collaborations, including deals with Anthropic and Microsoft, and referenced broader industry movement toward AI co-innovation labs. Nvidia demand from Big Pharma has been rising alongside parallel initiatives from other major players. The practical signal for the sector is that AI compute is becoming a core infrastructure decision tied directly to pipeline development and internal decision-making.